CTLA4 and hepatocellular carcinoma: In tremelimumab plus durvalumab treatment, the promotion of priming by CTLA4 blockade is an important pharmacological effect that significantly improved OS versus that with sorafenib, although PFS was not significantly different in advanced HCC patients [30].